NCT00573547

Open Label Trial of Fluoxetine for the Treatment of Depression in Patients With End Stage Renal Disease

A 12-Week Open-Label Trial of Once-Weekly Fluoxetine for the Treatment of Depression in Patients With End-Stage Renal Disease

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Creighton University · Academic / Other
• Sex: All
• Age: 19 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test whether once-weekly prozac therapy leads to reduction in depression in patients requiring kidney dialysis.

Detailed description

Once-weekly Prozac is a psychiatric medicine, approved by the FDA for the use in treatment of psychiatric disorders. This study will test whether once-weekly Prozac leads to reduced symptoms of depression. Patients requiring dialysis often report symptoms of depression either due to the presence of major depression, a relatively common psychiatric disorder, or due to depression secondary to kidney failure.

Conditions

• Depression

Interventions

Type	Name	Description
DRUG	Fluoxetine	Fluoxetine will be dosed at 90 mg once a week

Timeline

• Start date: 2007-02-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2007-12-14
• Last updated: 2011-08-16

Locations

2 sites across 1 country: United States